Simvastatin Inhibits Human Breast Cancer Migration Through Rho/Rho-Associated Coiled-Coil-Containing Protein Kinase Signaling

Yulian, Erwin Danil; Bustami, Arleni; Dosan, Ricky; Tantry, Harry Prawira; Rizanti, Fiola

doi:10.1166/asl.2017.9398

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, lovastatin, atorvastatin, and simvastatin have been shown to reduce metastatic seeding of melanoma and breast cancer cells in the lung and bone [ 85 , 89 , 93 ]. In breast cancer patients receiving 40 mg simvastatin per day for 4–6 weeks before mastectomy, statin treatment was able to decrease post-explant tumor migration [ 94 ]. Moreover, simvastatin treatment reduced the activity of Rho associated protein kinase (ROCK) and expression of RhoC, chemokine receptor type 4 (CXCR4), and CD44 [ 94 ].…”

Section: Basic Research Studiesmentioning

confidence: 99%

“…In breast cancer patients receiving 40 mg simvastatin per day for 4–6 weeks before mastectomy, statin treatment was able to decrease post-explant tumor migration [ 94 ]. Moreover, simvastatin treatment reduced the activity of Rho associated protein kinase (ROCK) and expression of RhoC, chemokine receptor type 4 (CXCR4), and CD44 [ 94 ]. In a sophisticated ex vivo microphysiological model of breast cancer metastasis to the liver, breast cancer outgrowth in response to an inflammatory lipopolysaccharide/EGF stimulus could be suppressed with atorvastatin treatment [ 95 ].…”

Section: Basic Research Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Statin drugs to reduce breast cancer recurrence and mortality

et al. 2018

View full text Add to dashboard Cite

Epidemiologic studies have, variably, shown the concomitant use of statin drugs to be beneficial to cancer outcomes. Statin drugs have been FDA approved for three decades for the treatment of high cholesterol and atherosclerotic coronary artery disease and are widely used. This has engendered studies as to their influence on concomitant diseases, including cancers. In this context, statin use has been correlated, variably, with a decrease in deaths from breast cancer. However, there is no extant model for this effect, and the extent of efficacy is open to question.The overarching goal of this article is to communicate to the reader of the potential of statins to reduce breast cancer progression and mortality. This is the use as a secondary prevention measure, and not as a therapy to directly counter active cancer. First, salient aspects of statin pharmacology, as relates to cardiovascular disease, will be discussed. Second, the basic and clinical research studies that investigate statin usage in breast cancer will be presented. Additionally, statin effects in other cancer types will be included for context. Finally, proposals for future basic and clinical research studies to determine the role of statins in breast cancer management will be presented.Electronic supplementary materialThe online version of this article (10.1186/s13058-018-1066-z) contains supplementary material, which is available to authorized users.

show abstract